Clinical interests include diagnostic immunohematology, blood donor safety and transfusion therapy. Research interests include platelet alloimmunization, microbial contamination of blood products, error management and systems approach to transfusion safety.
Dr. Elena Nedelcu brings two decades of experience in clinical pathology, transfusion medicine, hematology diagnostics and cellular therapies. Her main interests are medical and post-graduate education, patient safety and quality in transfusion service, and cellular therapies.
Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors. Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. Dr.
I am currently the Director of the Center for Research in Transfusion Medicine and Cellular Therapies at UCSF (CTMCT). This center is focused on bringing together multidisciplinary groups of individuals to collaborate in the areas of transfusion medicine (TM) and cellular therapies (CT). I am by training a translational vascular biologist with an interest in the role of endothelial dysfunction and vascular compromise in the pathogenesis of human disease.
Despite nearly three decades of focused research since the discovery of HIV-1, to date there is no cure or effective prophylactic vaccine for HIV-1 infection. Although the advent of Highly Active Antiretroviral Therapy (HAART) has dramatically decreased the morbidity and mortality associated with HIV-1 infection, there is a pronounced demand for alternative clinical management strategies due to frequent evolution of antiretroviral resistance, toxicity, and access constraints in resource-limited settings.
Dr. Raja has over 30 years of experience in studying the basic and clinical aspects of Histocompatibility and Immunogenetics. During the Ph.D. program in the Department of Transplantation Immunology and Immunogenetics, All India Institute of Medical Sciences, Dr. Raja developed DNA-based HLA typing method and studied the diversity of HLA in Asian Indians, and the association between HLA alleles and infectious diseases. During 6 years of postdoctoral training in the Parham laboratory, Stanford University, Dr. Raja defined the KIR genomic diversity in several non-human species. In 2002, Dr.
The Tang lab focuses on translating knowledge on mechanisms of immune tolerance into novel therapeutics for treating autoimmune diabetes and preventing transplant rejection. Currently, two major areas of work are on therapeutic application of regulatory T cell therapy in type 1 diabetes and transplantation and immune modulation to enable immune suppression-free transplant of stem-cell-derived beta cells for treatment of type 1 diabetes.
